What is the share price of SMS Pharmaceuticals Ltd (SMSPHARMA) today?
The share price of SMSPHARMA as on 5th December 2025 is ₹314.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on SMS Pharmaceuticals Ltd (SMSPHARMA) share?
The past returns of SMS Pharmaceuticals Ltd (SMSPHARMA) share are- Past 1 week: -1.92%
- Past 1 month: 13.94%
- Past 3 months: 38.29%
- Past 6 months: 26.85%
- Past 1 year: 22.86%
- Past 3 years: 280.92%
- Past 5 years: 237.29%
What are the peers or stocks similar to SMS Pharmaceuticals Ltd (SMSPHARMA)?
The peers or stocks similar to SMS Pharmaceuticals Ltd (SMSPHARMA) include:What is the dividend yield % of SMS Pharmaceuticals Ltd (SMSPHARMA) share?
The current dividend yield of SMS Pharmaceuticals Ltd (SMSPHARMA) is 0.12.What is the market cap of SMS Pharmaceuticals Ltd (SMSPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of SMS Pharmaceuticals Ltd (SMSPHARMA) is ₹3019.81 Cr as of 5th December 2025.What is the 52 week high and low of SMS Pharmaceuticals Ltd (SMSPHARMA) share?
The 52-week high of SMS Pharmaceuticals Ltd (SMSPHARMA) is ₹335 and the 52-week low is ₹176.05.What is the PE and PB ratio of SMS Pharmaceuticals Ltd (SMSPHARMA) stock?
The P/E (price-to-earnings) ratio of SMS Pharmaceuticals Ltd (SMSPHARMA) is 43.68. The P/B (price-to-book) ratio is 4.72.Which sector does SMS Pharmaceuticals Ltd (SMSPHARMA) belong to?
SMS Pharmaceuticals Ltd (SMSPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy SMS Pharmaceuticals Ltd (SMSPHARMA) shares?
You can directly buy SMS Pharmaceuticals Ltd (SMSPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
SMS Pharmaceuticals Ltd
SMSPHARMA Share Price
314.202.56% (-8.25)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SMSPHARMA Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
SMSPHARMA Performance & Key Metrics
SMSPHARMA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 35.80 | 4.72 | 0.12% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
SMSPHARMA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SMSPHARMA Company Profile
SMS Pharmaceuticals Limited is engaged in manufacturing and sale of bulk drugs and active pharmaceutical ingredients (APIs), and their intermediates.
SUNPHARMA
PE Ratio
39.92
39.92
1Y Return
1.01%
1.01%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.21
67.21
1Y Return
13.21%
13.21%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.34%
1.34%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.81
18.81
1Y Return
5.10%
5.10%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.12
29.12
1Y Return
0.46%
0.46%
Buy Reco %
72.22
72.22
SMSPHARMA Sentiment Analysis
SMSPHARMA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SMSPHARMA Stock Summary · November 2025
The company has demonstrated impressive financial growth, with an 80% year-on-year increase in Profit After Tax, driven by robust revenue and margin expansion. Its nearly three-decade market presence, coupled with backward integration and vertical manufacturing, enhances cost efficiency and positions it favorably against competitors, particularly in the API sector. While the Anti-diabetic segment faces challenges from increased competition, the company is strategically expanding its product portfolio and production capacities, supported by a significant capital expenditure program. Additionally, the Antiretroviral segment is poised for growth due to recent tender awards, providing a stable outlook. Overall, the company’s commitment to R&D and operational optimization underpins its confidence in achieving targeted growth and maintaining healthy margins.
SMSPHARMA Stock Growth Drivers
SMSPHARMA Stock Growth Drivers
6Strong Financial Performance
SMS Pharmaceuticals has reported a significant financial performance, with an 80% year-on-year growth in Profit
Backward Integration Strategy
The company emphasizes the importance of backward integration in enhancing cost competitiveness, supply chain reliability,
SMSPHARMA Stock Challenges
SMSPHARMA Stock Challenges
0
Hmm, looks like there are nochallenges
SMSPHARMA Forecast
SMSPHARMA Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
SMSPHARMA
SMSPHARMA
Income
Balance Sheet
Cash Flow
Annual Normal View
SMSPHARMA Income Statement
SMSPHARMA Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 439.58 | 465.07 | 468.31 | 417.06 | 566.62 | 525.07 | 526.96 | 713.73 | 788.97 | 865.60 | ||||||||||
Raw Materials | 325.03 | 294.32 | 307.19 | 259.50 | 313.27 | 387.95 | 299.72 | 425.26 | 501.87 | 698.27 | ||||||||||
| Power & Fuel Cost | 18.23 | 22.57 | 21.75 | 18.99 | 23.31 | 32.58 | 35.97 | 47.12 | 56.76 | |||||||||||
| Employee Cost | 26.92 | 32.80 | 35.59 | 39.35 | 41.17 | 51.02 | 50.08 | 64.15 | 80.08 | |||||||||||
| Selling & Administrative Expenses | 10.23 | 9.67 | 9.84 | 10.18 | 19.02 | 21.12 | 25.28 | 28.31 | 37.32 | |||||||||||
| Operating & Other expenses | -17.42 | 9.97 | 0.40 | 3.90 | 45.27 | -87.41 | 56.46 | 27.66 | -32.27 | |||||||||||
EBITDA | 76.59 | 95.74 | 93.54 | 85.14 | 124.58 | 119.81 | 59.45 | 121.23 | 145.21 | 167.33 | ||||||||||
| Depreciation/Amortization | 19.18 | 19.90 | 19.27 | 22.07 | 22.28 | 32.15 | 32.13 | 31.52 | 34.34 | 37.11 | ||||||||||
| PBIT | 57.41 | 75.84 | 74.27 | 63.07 | 102.30 | 87.66 | 27.32 | 89.71 | 110.87 | 130.22 | ||||||||||
| Interest & Other Items | 15.82 | 15.48 | 11.92 | 12.32 | 11.19 | 19.16 | 21.97 | 23.60 | 18.54 | 20.85 | ||||||||||
| PBT | 41.59 | 60.36 | 62.35 | 50.75 | 91.11 | 68.50 | 5.35 | 66.11 | 92.33 | 109.37 | ||||||||||
| Taxes & Other Items | 13.09 | 28.59 | 22.31 | 19.18 | 28.60 | 6.28 | 12.41 | 16.28 | 23.20 | 25.01 | ||||||||||
| Net Income | 28.50 | 31.77 | 40.04 | 31.57 | 62.51 | 62.22 | -7.06 | 49.83 | 69.13 | 84.36 | ||||||||||
| EPS | 3.37 | 3.75 | 4.73 | 3.73 | 7.38 | 7.35 | -0.83 | 5.89 | 7.98 | 9.52 | ||||||||||
| DPS | 0.20 | 0.25 | 0.25 | 0.25 | 0.30 | 0.30 | 0.30 | 0.40 | 0.40 | 0.40 | ||||||||||
| Payout ratio | 0.06 | 0.07 | 0.05 | 0.07 | 0.04 | 0.04 | — | 0.07 | 0.05 | 0.04 |
SMSPHARMA Company Updates
FY 2026FY 2026
Investor Presentation
Nov 10PDF
Aug 10PDF
SMSPHARMA Stock Peers
SMSPHARMA Past Performance & Peer Comparison
SMSPHARMA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| SMS Pharmaceuticals Ltd | 43.68 | 4.72 | 0.12% |
| Sun Pharmaceutical Industries Ltd | 39.92 | 6.02 | 0.88% |
| Torrent Pharmaceuticals Ltd | 67.21 | 16.92 | 0.84% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
SMSPHARMA Stock Price Comparison
Compare SMSPHARMA with any stock or ETFCompare SMSPHARMA with any stock or ETF
SMSPHARMA
SMSPHARMA Holdings
SMSPHARMA Shareholdings
SMSPHARMA Promoter Holdings Trend
SMSPHARMA Promoter Holdings Trend
Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has increased by 1.80%
High Pledged Promoter Holding
Lower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
SMSPHARMA Institutional Holdings Trend
SMSPHARMA Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 1.52%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SMSPHARMA Shareholding Pattern
SMSPHARMA Shareholding Pattern
SMSPHARMA Shareholding History
SMSPHARMA Shareholding History
Foreign Institutions
Mutual Funds Invested in SMSPHARMA
Mutual Funds Invested in SMSPHARMA
No mutual funds holding trends are available
Top 3 Mutual Funds holding SMS Pharmaceuticals Ltd
| Funds (Top 3) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.7594% | Percentage of the fund’s portfolio invested in the stock 0.17% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 91/118 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8298% | Percentage of the fund’s portfolio invested in the stock 6.53% | Change in the portfolio weight of the stock over the last 3 months 1.76% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/40 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0004% | Percentage of the fund’s portfolio invested in the stock 0.06% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 93/124 (+1) |
Compare 3-month MF holding change on Screener
smallcases containing SMSPHARMA stock
smallcases containing SMSPHARMA stock
Looks like this stock is not in any smallcase yet.
SMSPHARMA Events
SMSPHARMA Events
SMSPHARMA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SMSPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.12%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.17 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SMSPHARMA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SMSPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.12%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.17 every year
SMSPHARMA Upcoming Dividends
SMSPHARMA Upcoming Dividends
No upcoming dividends are available
SMSPHARMA Past Dividends
SMSPHARMA Past Dividends
Cash Dividend
Ex DateEx DateSep 22, 2025
Final
Final | Div/Share: ₹0.40
Dividend/Share
₹0.40
Ex DateEx Date
Sep 22, 2025
Cash Dividend
Ex DateEx DateSep 23, 2024
Final
Final | Div/Share: ₹0.40
Dividend/Share
₹0.40
Ex DateEx Date
Sep 23, 2024
Cash Dividend
Ex DateEx DateSep 22, 2023
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Sep 22, 2023
Cash Dividend
Ex DateEx DateSep 22, 2022
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Sep 22, 2022
Cash Dividend
Ex DateEx DateSep 22, 2021
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Sep 22, 2021
SMSPHARMA Stock News & Opinions
SMSPHARMA Stock News & Opinions
Articles & Videos
Corporate
SMS Pharmaceuticals receives revision in credit ratings from CARE
SMS Pharmaceuticals has received revision in credit ratings from CARE Ratings as under: Long term bank facilities (Rs 350.87 crore) - CARE A; Positive (reaffirmed, outlook revised from Stable) Short term bank facilities (Rs 52.83 crore) - CARE A1 (upgraded from CARE A2+) Powered by Capital Market - Live
22 hours agoCapital Market - Live
Spotlight
SMS Pharma spurts after associate firm secures USFDA nod for reformulated Ranitidine tablets
This approval marks the re-entry of this important acid-reducing medication into the US market after a five-year absence. The product had previously been withdrawn over concerns related to the formation of NDMA, a potential carcinogenic impurity. According to the company, the approval by the US FDA comes after extensive safety testing and manufacturing improvements that address previous concerns regarding the formation of NDMA impurity. It is expected to increase patient access to this important medication for patients who rely on it for various health conditions. SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag. The company's consolidated net profit jumped 79.5% to Rs 25.31 crore on 23.2% increase in revenue from operations to Rs 242.43 crore in Q2 FY26 over Q2 FY25. Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
SMS Pharmaceuticals' associate company receives USFDA approval for Ranitidine tablets
SMS Pharmaceuticals announced that the US Food and Drug Administration has approved its associate company VKT Pharma's reformulated Ranitidine tablets in 150mg and 300mg strengths. This approval marks the re-entry of this important acid-reducing medication into the US market after a five-year absence. The approval by the US FDA comes after extensive safety testing and manufacturing improvements that address previous concerns regarding the formation of NDMA impurity. It is expected to increase patient access to this important medication for patients who rely on it for various health conditions. Powered by Capital Market - Live
1 week agoCapital Market - Live
Spotlight
SMS Pharma spurts after Q2 PAT climbs 79% YoY to Rs 25 cr
Profit before tax (PBT) increased 74.21% YoY to Rs 34.04 crore in Q2 FY26. Total expenses climbed 17.55% to Rs 209.82 crore in Q2 FY26, compared with Rs 178.50 crore in Q2 FY25. Cost of material consumed stood at Rs 106.56 crore (down 32.88% YoY), manufacturing expenses stood at Rs 25.73 crore (up 17.01% YoY), employee benefit expenses was at Rs 19.25 crore (up 7.42% YoY) and finance cost stood at Rs 5.73 crore (up 24.57% YoY) during the period under review. On half yearly basis, the company's consolidated net profit jumped 49.8% to Rs 45.80 crore on 21.4% increase in revenue from operations to Rs 438.48 crore in H1 FY26 over H1 FY25. SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
SMS Pharmaceuticals consolidated net profit rises 79.50% in the September 2025 quarter
Net profit of SMS Pharmaceuticals rose 79.50% to Rs 25.31 crore in the quarter ended September 2025 as against Rs 14.10 crore during the previous quarter ended September 2024. Sales rose 23.22% to Rs 242.43 crore in the quarter ended September 2025 as against Rs 196.75 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales242.43196.75 23 OPM %19.9515.99 - PBDT44.0628.16 56 PBT34.0419.54 74 NP25.3114.10 80 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
SMS Pharmaceuticals declare Quarterly Result
SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
SMS Pharmaceuticals to conduct AGM
SMS Pharmaceuticals announced that the 37th Annual General Meeting(AGM) of the company will be held on 29 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
SMS Pharmaceuticals consolidated net profit rises 24.33% in the June 2025 quarter
Net profit of SMS Pharmaceuticals rose 24.33% to Rs 20.49 crore in the quarter ended June 2025 as against Rs 16.48 crore during the previous quarter ended June 2024. Sales rose 19.22% to Rs 196.05 crore in the quarter ended June 2025 as against Rs 164.45 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales196.05164.45 19 OPM %20.0820.38 - PBDT34.1230.21 13 PBT24.3721.83 12 NP20.4916.48 24 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
SMS Pharmaceuticals fixes record date for dividend
SMS Pharmaceuticals has fixed 22 September 2025 as record date for the purpose of determining the Members eligible to receive dividend for the financial year 2024-25. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
SMS Pharmaceuticals to convene board meeting
SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 13.6%, vs industry avg of 10.03%
Over the last 5 years, market share increased from 0.17% to 0.19%
Over the last 5 years, net income has grown at a yearly rate of 16.97%, vs industry avg of 20.02%